Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rapid HIV-1 tests

This article was originally published in The Gray Sheet

Executive Summary

CLIA-waived status for the tests is being pursued by an HIV coalition supported by the President's Advisory Council on HIV/AIDS and the Congressional Black Caucus. "We call on [FDA and CMS] to release HIV rapid tests with CLIA waiver immediately," the groups state in an Oct. 24 release, arguing that state regulations provide sufficient safeguards. OraSure received a May "approvable" letter from FDA for its OraQuick rapid HIV test, requiring resolution of "specific validation and control issues" before agency sign-off (1"The Gray Sheet" June 24, 2002, p. 22)...

You may also be interested in...



OraSure License/Marketing Pact With Abbott To Aid OraQuick HIV Test Launch

OraSure Technologies' license of non-exclusive rights to certain test strip technology patents from Abbott appears to clear the way for a U.S. launch of OraSure's OraQuick rapid HIV-1 test, pending FDA approval

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel